Savara Quarterly Income Statement
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.92+0.09 (+1.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Savara revenue and earnings
Savara reported a net loss of $40.2 million, compared with a loss of $30.4 million a year earlier. Diluted earnings per share came in at -$0.16.
Summary generated from market data by MetaCap's automated system. Methodology
Savara income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 40.97M | 38.99M | 33.42M | 30.25M | 31.44M | 28.43M | 31.17M | 26.36M | 23.19M | 22.48M | 17.63M | 18.04M |
| Research & Development | 21.95M | 23.40M | 20.90M | 20.59M | 20.75M | 19.16M | 23.29M | 20.31M | 17.62M | 16.81M | 12.75M | 13.87M |
| Operating Income | -40.97M | -38.99M | -33.42M | -30.25M | -31.44M | -28.43M | -31.17M | -26.36M | -23.19M | -22.48M | -17.63M | -18.04M |
| Other Income (Expense) | 737.00K | 1.71M | 1.18M | 694.00K | 1.04M | 1.80M | 2.13M | 2.11M | 947.00K | 2.13M | 1.53M | 1.45M |
| Pretax Income | — | — | — | — | — | -26.64M | — | — | — | -20.35M | — | — |
| Net Income | -40.23M | -37.28M | -32.24M | -29.56M | -30.40M | -26.64M | -29.04M | -24.25M | -22.24M | -20.35M | -16.10M | -16.60M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.16 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.14 | -0.11 | -0.12 | -0.11 | -0.09 | -0.10 |
| EPS (Diluted) | -0.16 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.14 | -0.11 | -0.12 | -0.11 | -0.09 | -0.10 |
| Shares Outstanding (Basic) | 253.57M | 253.28M | — | 216.46M | 216.43M | 216.15M | — | 211.85M | 182.58M | 182.55M | — | 174.70M |
| Shares Outstanding (Diluted) | 253.57M | 253.28M | — | 216.46M | 216.43M | 216.15M | — | 211.85M | 182.58M | 182.55M | — | 174.70M |
| EBITDA | -40.94M | -38.97M | -33.43M | -30.22M | -31.41M | -28.41M | -31.14M | -26.32M | -23.16M | -22.44M | -17.60M | -18.01M |
This table shows 12 quarterly periods of Savara's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SVRA's reporting calendar. What is a income statement?